GH1 and neoplasm: Decreased clinical SSA sensitivity may be related to the evolving tumor biology between surgeries, particularly the loss of tumoral somatostatin receptor (SSTR) 5 expression, whereas in vitro, there was no tumoral response of GH to pasireotide and cabergoline.